Nypozi — Medica

Initial criteria

• Patient meets ONE of the following (i, ii, iii, or iv):
• i. Patient is receiving myelosuppressive anti-cancer medications associated with high risk of febrile neutropenia (risk ≥ 20%)
• ii. Patient is receiving myelosuppressive anti-cancer medications with febrile neutropenia risk < 20% AND patient has at least one risk factor for febrile neutropenia according to prescriber
• iii. Patient had a neutropenic complication from a prior chemotherapy cycle without prophylactic colony stimulating factor AND a reduced chemotherapy dose may compromise treatment outcome
• iv. Patient who has received chemotherapy has febrile neutropenia and at least one risk factor for poor clinical outcomes or infection-associated complications according to prescriber
• Medication is prescribed by or in consultation with an oncologist or hematologist

Approval duration

6 months